About Us | Esco Aster

Mission and Vision

To be the leading cGMP CRDMO globally in adherent bioprocessing/ continuous processing using flow chemistry utilizing our own in house proprietary/patented platforms and accelerate the discovery to delivery process of vaccines (human, animal, cancer), oncolytic viruses, cell/gene therapy, tissue engineering, mabs/recombinant proteins, diagnostics, small molecules, cosmeceuticals, peptides, biopolymers, bioscaffolds, and cosmetics/fast-moving consumer goods (FMCG).

What We Do

We focus on offering vaccine-, bio-, cell- and gene-therapy development manufacturing services using primarily its proprietary Adherent Tide Motion Platform supplemented by single-use suspension and fermentation, downstream bioprocessing, and custom bioengineering equipment for client specific therapeutics.

Within the in vitro/in vivo Diagnostic space, we focus on developing mAb-based antigens, single-domain antibodies for radio imaging, RT PCR reagents, RCL diagnostics. We work with collaborators to provide turnkey mobile Dx labs: Aster Xpress™.

Within the chem- biopolymer- cosmetic, personal care, cosmeceutical segments, we excel in converting batch processes into continuous flow chemistry, closed aseptic processing within isolators and variety of skin safety/efficacy testing services.

For the COVID-19 pandemic we are working on an end-to-end trace, test, and treat platform from swab booths, to mobile labs, turnkey modular screening and treatment centres with isolation rooms as well as working on diagnostics, therapeutics, and vaccines.

Our Locations

Esco Aster operates on dedicated sites based on our applications of our manufacturing platforms, each site has dedicated scientists working on specific modalities. Esco Aster will continue to scale up with our collaborators and partners for future commercial expansion in Singapore or as Internal Tech Transfer to client choice of country. Facilities and applications are:

Esco AsterTide PD-Phase 2 CTM (Cells/Viruses/EVs)

#02-01 Blk 67 Ayer Rajah Crescent Singapore 139950

Esco AsterMavors Cellular Agriculture and Alternative Proteins (Food)

#03-20 Blk 71 Ayer Rajah Crescent Singapore 139951

Esco Aster Fermentation (Plasmids)

21 Changi South Street 1 Singapore 486777

Esco Aster COE China

Esco Aster COE India

• Esco Aster Singapore Manufacturing
• Esco Aster PD/Intermediates/Clinical Trial Material Operations

Esco Aster COE USA

Our Certifications

ISO 22000:2018

This certification demonstrates Esco Aster's ability to control food safety hazards and ensure that food is safe for consumption.

Key potential benefits of possessing this standard include:

the ability to consistently provide food-related products and services that are safe and meet regulatory requirements
improved management of risks in food safety processes

ISO 9001:2015

Esco Aster's ISO 9001:2015 ensures that its business operations are robust and lays a quality management system foundation for the organization including its developmental sciences and services for Good Laboratory Practices (GLP)

Key potential benefits of possessing this standard include:

the ability to consistently provide products and services that meet customer and applicable statutory and regulatory requirements for contract research and process development services for mammalian cells and their derivatives.
the ability to achieve customer satisfaction through the effective application of the system, including processes for improvement of the system and the assurance of conformity to customer and applicable statutory and regulatory requirements.

Our History

1978

Esco was founded in Singapore and began to pioneer cleanroom technology in Souteast Asia

1990

Esco expands distribution to pharmaceutical life science biotech and medical research markets

2001

Esco earns first EN 12469 cert. for BSC

2006

Esco earns onsite UL accreditation

2007

Expansion of Esco life science and medical products

2015

Esco VacciXcell was introduced

2017

Esco Aster was introduced (first CDMO company in Asia utilizing its own proprietry Tide Motion technology)

Esco Aster and Institue of Molecular Cell Biology announce a collaboration to accelerate pre-clinical development of a hand foot and mouth vaccine.

Esco Aster and Bioprocessing Institute sign a Memorandum of Understanding to innovate on continuous manufacturing platform.

2018

Esco Aster and National University of Singapore announce a development of single-use bioreactor-based stem cells for bone regeneration.

2019

Esco Aster continues to grow with the outfitting of a cGMP-compliant PD,GLP, Phase 1 and 2 clinical trial facility.

2021

Esco Aster Receives Food Processing License to Manufacture Cell-Based Cultivated Meat from Singapore Authorities

Our Senior Management

XL Lin

CEO, Founding President

XL Lin founded and manages the Esco Aster and Esco Healthcare Division within the Esco Lifesciences Group in 2009 developing the companies' very first cGMP downflow/containment booths and isolation systems from concept development to sales, project management, site-work, and validation.

Under his leadership, Esco Pharma has expanded from just a small division to now having 3 factories globally in USA/UK and Singapore. He brings his unique skillset in social entrepreneurship, market development, strategic product development, globally alliance networking, sales/contract management, clean air/containment facility, and systems design/integration into Esco VacciXcell. XL Lin graduated with a Bachelor of Sciences from University of Sydney and he is currently pursuing various options for further studies.